Vulnerabilities of the SARS-CoV-2 virus to proteotoxicity -- opportunity for repurposed chemotherapy of COVID-19 infection
M. Al-Motawa, H. Abbas, P. Wijten, A. de la Fuente, M. Xue, N. Rabbani, P. Thornalley
This paper identifies SARS-CoV-2 vulnerability to methylglyoxal and suggests repurposing doxorubicin and paclitaxel for COVID-19 treatment based on their ability to increase cellular methylglyoxal levels.
bioRxiv · Apr 7, 2020Biochemistry